{"component": "definition", "props": {"groups": [{"snippet_links": [], "samples": [{"hash": "dv1QK7B0aWi", "uri": "/contracts/dv1QK7B0aWi#jfc", "label": "Collaboration and License Agreement (Facet Biotech Corp)", "score": 21.2847366333, "published": true}, {"hash": "dFAuIortDj4", "uri": "/contracts/dFAuIortDj4#jfc", "label": "Collaboration and License Agreement (Trubion Pharmaceuticals, Inc)", "score": 21.2108154297, "published": true}, {"hash": "fXtvZWd168N", "uri": "/contracts/fXtvZWd168N#jfc", "label": "Collaboration and License Agreement (Trubion Pharmaceuticals, Inc)", "score": 21.0, "published": true}], "size": 5, "snippet": "has the meaning set forth in Section 2.1(a).", "hash": "d35e167b65d2195414541e0496edeec8", "id": 1}, {"snippet_links": [{"key": "section-971", "type": "clause", "offset": [29, 42]}], "samples": [{"hash": "83WWYAOgLcb", "uri": "/contracts/83WWYAOgLcb#jfc", "label": "Collaboration and License Agreement (Kymera Therapeutics, Inc.)", "score": 35.1409988403, "published": true}, {"hash": "l3SeuC4QJiw", "uri": "/contracts/l3SeuC4QJiw#jfc", "label": "Collaboration and License Agreement (Kymera Therapeutics, Inc.)", "score": 34.1444206238, "published": true}, {"hash": "3ebf1sSqNAi", "uri": "/contracts/3ebf1sSqNAi#jfc", "label": "Collaboration and License Agreement (Kymera Therapeutics, Inc.)", "score": 31.5790557861, "published": true}], "size": 5, "snippet": "has the meaning set forth in Section 9.7.1.", "hash": "05fa6437011b7f87112397a865974511", "id": 2}, {"snippet_links": [], "samples": [{"hash": "50EOgv60Jcd", "uri": "/contracts/50EOgv60Jcd#jfc", "label": "Collaboration and License Agreement (Zai Lab LTD)", "score": 32.3538665771, "published": true}, {"hash": "cOU863sYqjK", "uri": "/contracts/cOU863sYqjK#jfc", "label": "Collaboration and License Agreement (Argenx Se)", "score": 32.2416152954, "published": true}], "size": 5, "snippet": "has the meaning set forth in Section 2.5.", "hash": "fd85c2c1ffd623fd985f153487f37567", "id": 3}, {"snippet_links": [{"key": "section-45", "type": "clause", "offset": [29, 40]}, {"key": "joint-finance-committee", "type": "clause", "offset": [42, 65]}], "samples": [{"hash": "6zY23TDFh7A", "uri": "/contracts/6zY23TDFh7A#jfc", "label": "Research Collaboration and Option Agreement (Morphic Holding, Inc.)", "score": 30.4483222961, "published": true}, {"hash": "cBiWK15Lw3n", "uri": "/contracts/cBiWK15Lw3n#jfc", "label": "Research Collaboration and Option Agreement (Morphic Holding, Inc.)", "score": 30.4072551727, "published": true}, {"hash": "b285ETTr4rL", "uri": "/contracts/b285ETTr4rL#jfc", "label": "Research Collaboration and Option Agreement (Morphic Holding, Inc.)", "score": 30.3853530884, "published": true}], "size": 4, "snippet": "has the meaning set forth in Section 4.5 (Joint Finance Committee).", "hash": "ec75fd6d366852d3db759ee1275a4a1e", "id": 4}, {"snippet_links": [{"key": "the-committee", "type": "clause", "offset": [6, 19]}, {"key": "section-26", "type": "clause", "offset": [33, 44]}], "samples": [{"hash": "hOAxEpZ87oE", "uri": "/contracts/hOAxEpZ87oE#jfc", "label": "Collaboration Agreement (Exelixis Inc)", "score": 22.5879535675, "published": true}, {"hash": "agLjtPfd9Af", "uri": "/contracts/agLjtPfd9Af#jfc", "label": "Collaboration Agreement (Exelixis Inc)", "score": 21.0, "published": true}], "size": 4, "snippet": "means the committee described in Section 2.6.", "hash": "0d89c63db7bfc6e65521471cf8b1953e", "id": 5}, {"snippet_links": [{"key": "committee-established", "type": "clause", "offset": [11, 32]}, {"key": "section-34", "type": "clause", "offset": [45, 56]}, {"key": "collaboration-agreement", "type": "definition", "offset": [64, 87]}], "samples": [{"hash": "3TQUM8XQbfr", "uri": "/contracts/3TQUM8XQbfr#jfc", "label": "Collaboration Agreement (Biogen Idec Inc.)", "score": 22.0924034119, "published": true}, {"hash": "iLy8aaY6QuA", "uri": "/contracts/iLy8aaY6QuA#jfc", "label": "Collaboration Agreement (Genentech Inc)", "score": 21.0, "published": true}, {"hash": "7ccpbupvKVc", "uri": "/contracts/7ccpbupvKVc#jfc", "label": "Collaboration Agreement (Idec Pharmaceuticals Corp / De)", "score": 21.0, "published": true}], "size": 3, "snippet": "means that committee established pursuant to Section 3.4 of the Collaboration Agreement.", "hash": "19da60b4e71c86cd697a7f9684b8d1cd", "id": 6}, {"snippet_links": [{"key": "company-organized", "type": "clause", "offset": [25, 42]}, {"key": "the-laws", "type": "definition", "offset": [49, 57]}, {"key": "subsidiary-of", "type": "definition", "offset": [80, 93]}], "samples": [{"hash": "TcNclVnwbe", "uri": "/contracts/TcNclVnwbe#jfc", "label": "Loan and Security Agreement (Aerocentury Corp)", "score": 29.3408622742, "published": true}, {"hash": "gKz2kmO7mUo", "uri": "/contracts/gKz2kmO7mUo#jfc", "label": "Loan and Security Agreement (Aerocentury Corp)", "score": 28.2101306915, "published": true}, {"hash": "aWnifjTc2mQ", "uri": "https://www.snl.com/Cache/IRCache/f6777464-4c89-8cbb-efd8-e60f1db41fe7.pdf", "label": "www.snl.com", "score": 10.5373029709, "published": false}], "size": 3, "snippet": "means JetFleet Canada, a company organized under the laws of Canada, which is a Subsidiary of JMC.", "hash": "8ee7f8d861cd14adb7bfca5eb1867dca", "id": 7}, {"snippet_links": [{"key": "joint-finance-committee", "type": "clause", "offset": [10, 33]}, {"key": "section-32", "type": "definition", "offset": [48, 59]}, {"key": "this-agreement", "type": "clause", "offset": [63, 77]}], "samples": [{"hash": "kINXn97nVt7", "uri": "/contracts/kINXn97nVt7#jfc", "label": "License and Collaboration Agreement (Tercica Inc)", "score": 21.0, "published": true}, {"hash": "6oyAQ28gEoA", "uri": "/contracts/6oyAQ28gEoA#jfc", "label": "License and Collaboration Agreement (Tercica Inc)", "score": 21.0, "published": true}], "size": 2, "snippet": "means the joint finance committee as defined in Section 3.2 of this Agreement.", "hash": "bee38a046f108a62f6fae7c4f999e08d", "id": 8}, {"snippet_links": [{"key": "section-31", "type": "clause", "offset": [29, 40]}], "samples": [{"hash": "g0Hy5DrdhSB", "uri": "/contracts/g0Hy5DrdhSB#jfc", "label": "Co Development, License and Co Promotion Agreement (Nektar Therapeutics)", "score": 22.1608486176, "published": true}], "size": 2, "snippet": "has the meaning set forth in Section 3.1.", "hash": "3d19223e249d2e344053d0014b14d616", "id": 9}, {"snippet_links": [{"key": "pursuant-to-section", "type": "clause", "offset": [47, 66]}], "samples": [{"hash": "kzTY0wGgzN7", "uri": "/contracts/kzTY0wGgzN7#jfc", "label": "Co Development and Commercialization Agreement (Protein Design Labs Inc/De)", "score": 21.0, "published": true}], "size": 1, "snippet": "means that subcommittee of the JSC established pursuant to Section 3.3(g).", "hash": "d4e5fee407f296a0949f9757da8e7bb5", "id": 10}], "next_curs": "ClASSmoVc35sYXdpbnNpZGVyY29udHJhY3RzciwLEhpEZWZpbml0aW9uU25pcHBldEdyb3VwX3Y1NiIMamZjIzAwMDAwMDBhDKIBAmVuGAAgAA==", "definition": {"title": "JFC", "size": 44, "snippet": "has the meaning set forth in Section 2.1(a).", "id": "jfc", "examples": ["The Alliance Managers or their designees may attend <strong>JFC</strong> meetings in a non-voting capacity.", "The <strong>JFC</strong> will be comprised of two representatives of Company and two representatives of Vir Bio (or such other equal number of representatives as the <strong>JFC</strong> may determine), including each Party\u2019s Finance Lead.", "Each Party shall designate one of its <strong>JFC</strong> representatives as such Party\u2019s financial lead (\u201cFinance Lead\u201d).", "Each Party may change its respective representatives to the <strong>JFC</strong> from time to time, in its sole discretion, effective upon notice to the other Party designating such change.", "The Parties will coordinate all activities related to the Development Cost Share through the <strong>JFC</strong> and in accordance with the terms of this Agreement.", "The <strong>JFC</strong> will immediately disband and terminate upon the earlier of (i) expiration or termination of this Agreement in its entirety and (ii) following the Opt-Out Effective Date, the payment of the final Balancing Payment under Section 8.3 (Reports and Payments).", "Once the Finance Leads have completed their review of the Quarterly CFS, Balancing Amount, and balancing statement, the Finance Leads will present such Quarterly CFS, Balancing Amount, and balancing statements to the <strong>JFC</strong> at the next meeting of the <strong>JFC</strong>."], "related": [["jcc", "JCC", "JCC"], ["jmc", "JMC", "JMC"], ["jdc", "JDC", "JDC"], ["jrc", "JRC", "JRC"], ["jsc", "JSC", "JSC"]], "related_snippets": [], "updated": "2026-05-10T05:39:37+00:00"}, "json": true, "cursor": ""}}